SYROS PHARMACEUTICALS INC (SYRS) Stock Analyst Ratings
USA - NASDAQ:SYRS - US87184Q2066 - Common Stock
0.1172 USD
-0.01 (-8.44%)
0.1072 USD
-0.01 (-8.53%)
ChartMill assigns a Buy % Consensus number of 78% to SYRS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.71. This target is 9038.23% above the current price.
SYRS was analyzed by 9 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about SYRS.
In the previous month the buy percentage consensus was at a similar level.
SYRS was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-13 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-11-13 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-11-13 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2024-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-08-13 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-03 | Oppenheimer | Maintains | Outperform |
| 2023-03-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-05 | Piper Sandler | Maintains | Overweight |
| 2022-11-15 | JMP Securities | Maintains | Market Outperform |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-10 | Oppenheimer | Maintains | Outperform |
| 2022-07-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | Alliance Global Partners | Maintains | Buy |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-23 | Roth Capital | Maintains | Buy |
SYROS PHARMACEUTICALS INC / SYRS FAQ
What is the average price target for SYROS PHARMACEUTICALS INC (SYRS) stock?
9 analysts have analysed SYRS and the average price target is 10.71 USD. This implies a price increase of 9038.23% is expected in the next year compared to the current price of 0.1172.
How do analysts rate SYROS PHARMACEUTICALS INC (SYRS)?
The consensus rating for SYROS PHARMACEUTICALS INC (SYRS) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.